cd318-car-t cells
Cell therapyexperimental
Clinical trial activity
1 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2026 (NCT07153289)
Timeline
2020s
- Jan 1, 2026
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CUB domain-containing protein 1Immunity, passive
CDCP1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07153289 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2026 | Berlin Institute of Health, Julius-Maximilians University, Miltenyi Biotec, Inc., Technical University of Munich, University of Freiburg, University of Heidelberg, University of Tuebingen |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Berlin Institute of Health | Academic/Hospital | 1 | 0 | 1 | 2026 |
| Julius-Maximilians University | Academic/Hospital | 1 | 0 | 1 | 2026 |
| Miltenyi Biotec, Inc. | For profit | 1 | 0 | 1 | 2026 |
| Technical University of Munich | Academic/Hospital | 1 | 0 | 1 | 2026 |
| University of Freiburg | Academic/Hospital | 1 | 0 | 1 | 2026 |
| University of Heidelberg | Academic/Hospital | 1 | 0 | 1 | 2026 |
| University of Tuebingen | Academic/Hospital | 1 | 1 | 1 | 2026 |
7 organizations
Page 1 / 1